Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Clinical course of adults living with cystic fibrosis in terms of glucose tolerance in the era of modulator therapies

EF 2024-25

Résumé
Cystic fibrosis (CF) is a genetic disease caused by a mutation that results in pulmonary and digestive complications, thereby decreasing life expectancy. Improvements in health care and therapeutic discoveries have increased the median age of survival of Canadians with CF from less than 37 years old in 2002 to around 60 years today. This spectacular improvement has been accompanied by new complications, notably CF related diabetes (CFRD). CFRD is a specific form of diabetes that shares characteristics of type 1 diabetes (decreased insulin secretion) and type 2 diabetes (insulin resistance). Development of CFRD is associated with an increased risk of pulmonary dysfunction and weight deterioration. Revolutionary genetic medications (highly effective modulator treatments) have recently been developed. These modulators target the cause of CF, which results in improved pulmonary function, weight, and quality of life. However, the impact of modulators on CFRD incidence and underlying mechanisms (insulin secretion and insulin resistance) is not well understood. We have access to a prospective cohort (n=389), established 20 years ago (2004), in which participants with CF undergo testing every 18 months for weight, pulmonary function, glucose tolerance (oral glucose tolerance test), glycated hemoglobin, and insulin secretion/resistance (glycemia and insulinemia). Over the past 5 years, 70% of participants initiated treatment with modulators. This allows us to compare the incidence of CFRD before and after initiation of modulators and to investigate their impact on glucose tolerance and underlying mechanisms. We anticipate these revolutionary modulators will change the risk and progression of CFRD. This study is critical in guiding future CFRD screening and management decisions.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529978
Name
Girouard Heather
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Clinical course of adults living with cystic fibrosis in terms of glucose tolerance in the era of modulator therapies
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cystic Fibrosis; Cystic Fibrosis Related Diabetes; Glucose; Insulin; Modulators; Trikafta
Abstract
Cystic fibrosis (CF) is a genetic disease caused by a mutation that results in pulmonary and digestive complications, thereby decreasing life expectancy. Improvements in health care and therapeutic discoveries have increased the median age of survival of Canadians with CF from less than 37 years old in 2002 to around 60 years today. This spectacular improvement has been accompanied by new complications, notably CF related diabetes (CFRD). CFRD is a specific form of diabetes that shares characteristics of type 1 diabetes (decreased insulin secretion) and type 2 diabetes (insulin resistance). Development of CFRD is associated with an increased risk of pulmonary dysfunction and weight deterioration. Revolutionary genetic medications (highly effective modulator treatments) have recently been developed. These modulators target the cause of CF, which results in improved pulmonary function, weight, and quality of life. However, the impact of modulators on CFRD incidence and underlying mechanisms (insulin secretion and insulin resistance) is not well understood. We have access to a prospective cohort (n=389), established 20 years ago (2004), in which participants with CF undergo testing every 18 months for weight, pulmonary function, glucose tolerance (oral glucose tolerance test), glycated hemoglobin, and insulin secretion/resistance (glycemia and insulinemia). Over the past 5 years, 70% of participants initiated treatment with modulators. This allows us to compare the incidence of CFRD before and after initiation of modulators and to investigate their impact on glucose tolerance and underlying mechanisms. We anticipate these revolutionary modulators will change the risk and progression of CFRD. This study is critical in guiding future CFRD screening and management decisions.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Girouard, Heather
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~